TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07768189: A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

Sponsor: Corbus Pharmaceuticals Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 260 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT07768189 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07768189 Rescue Dossier →